Living Cell Technologies (ASX:LCT) Present Novel Parkinson’s Disease Treatment Results

LCT is a global leader in developing cell transplant therapies to treat chronic disease and NTCELL is LCT’s lead product for treatment of neurodegenerative disorders. NTCELL has been developed using LCT’s pioneering animal-cell-based transplantation and encapsulation platform.

The pre-clinical studies were performed in animals in which a Parkinson’s-like condition had been induced. In all of the studies, transplantation of NTCELL into the affected brain regions reduced movement disorders and neurological defects associated with the disease compared to controls, which received only empty capsules. The improvements in symptoms were seen within two weeks and persisted for at least six months, the end-point of the trial. Microscopic analysis of both treated and untreated brain regions clearly showed an increase in the number of dopamine producing neurons in the NTCELL treated subjects compared to controls. In addition, there was no cellular or pathological evidence of inflammation or other adverse event.

Professor Robert Elliott said, “Today we have presented a comprehensive suite of pre-clinical data in small animal and non-human primate studies which show an astonishing recovery of the part of the brain affected in Parkinson’s disease, as well as a more than 50% improvement in the devastating movement and neurological symptoms of the disease. We are now compiling an application to New Zealand’s medicines safety authority, Medsafe, to start Phase I clinical trials in Parkinson’s patients. Pending regulatory authorisation, LCT expects to begin these trials by the end of Q1 2013.”

Dr Andrea Grant, Chief Executive Officer of LCT said, “BioPharma Asia is the leading forum through which the most influential decision makers in the Asian and global biopharmaceutical industry forge partnerships. We are delighted to have been invited to present our unprecedented results of NTCELL in Parkinson’s as a plenary.”

About Living Cell Technologies Limited

Living Cell Technologies Limited (ASX:LCT) (OTCQX:LVCLY) is developing cell-based products to treat life threatening human diseases. The Company holds 50% of Diatranz Otsuka Limited which owns a bio-certified pig herd that it uses as a source of cells and DIABECELL(R) which is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. Using breakthrough proprietary microencapsulation technology, IMMUPEL(TM), which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson’s disease, Huntington’s disease, stroke, and hearing loss. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.


Source: ABN Newswire


0 Condivisioni